Pathophysiology and therapeutic targets for ischemic stroke.
The increased risk for stroke among those who have had a previous stroke or transient ischemic attack (TIA) and the tremendous burden of disability among stroke sufferers make both primary and secondary preventative strategies imperative. An understanding of the pathophysiology of stroke and TIA can help identify appropriate therapeutic targets.
Levine
Steven R
SR
Stroke Program, Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA. steven.levine@mssm.edu
D000208:Acute Disease; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy / Q000503:physiopathology*
D010975:Platelet Aggregation Inhibitors